What is Genisphere?
Genisphere is a biotechnology firm dedicated to the advancement of its 3DNA Precision Medicine Platform. This innovative platform employs a unique nanoscale scaffold derived from synthetic DNA to facilitate the precise, intracellular delivery of therapeutic agents. The company's primary focus is on developing treatments for neuroinflammatory diseases, and it actively pursues strategic partnerships to enhance the efficacy and safety of its drug delivery systems. Genisphere's objective is to maximize the potential of its platform through collaborations across academic and industrial sectors, targeting a range of medical conditions including neurodegenerative disorders and various forms of cancer.
How much funding has Genisphere raised?
Genisphere has raised a total of $13.2M across 4 funding rounds:
Private Equity
$2M
Private Equity
$4M
Unspecified
$7M
Debt
$150K
Private Equity (2014): $2M with participation from Corporate Fuel Securities
Private Equity (2015): $4M led by Lankenau Institute for Medical Research
Unspecified (2017): $7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Genisphere
Lankenau Institute for Medical Research
The Lankenau Institute for Medical Research is an institution likely involved in pioneering medical research, contributing to Genisphere's development in the biotechnology and rare disease treatment space.
Corporate Fuel Securities
Corporate Fuel Securities, an investment bank specializing in middle-market advisory and capital raising, has provided backing, indicating a strategic financial partnership to support Genisphere's growth initiatives.
PPP
Public-Private Partnership
What's next for Genisphere?
The recent major strategic investment in Genisphere signals a critical phase of growth and development for the company. With a focus on its 3DNA Precision Medicine Platform, Genisphere is poised to accelerate its therapeutic pipeline, particularly for rare and neuroinflammatory diseases. Future endeavors will likely involve expanding its research and development capabilities, forging new strategic alliances to broaden the application of its technology, and potentially advancing its lead candidates through clinical trials. This capital infusion is expected to bolster its efforts in maximizing the platform's value and addressing unmet medical needs in oncology and neurodegenerative conditions.
See full Genisphere company page
